CoChat

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Open access
Dasari, Arvind, Lonardi, Sara, Garcia-Carbonero, Rocio, Elez, Elena, Yoshino, Takayuki, Sobrero, Alberto, Yao, James, García-Alfonso, Pilar, Kocsis, Judit, Cubillo Gracian, Antonio, Sartore-Bianchi, Andrea, Satoh, Taroh, Randrian, Violaine, Tomasek, Jiri, Chong, Geoff, Paulson, Andrew Scott, Masuishi, Toshiki, Jones, Jeremy, Csőszi, Tibor, Cremolini, Chiara, Ghiringhelli, Francois, Shergill, Ardaman, Hochster, Howard S, Krauss, John, Bassam, Ali, Ducreux, Michel, Elme, Anneli, Faugeras, Laurence, Kasper, Stefan, Van Cutsem, Eric, Arnold, Dirk, Nanda, Shivani, Yang, Zhao, Schelman, William R, Kania, Marek, Tabernero, Josep, Eng, Cathy · 2023 · The Lancet

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3, in patients with heavily pretreated metastatic colorectal cancer.Methods We conducted an international, randomised, double-blind, placebo-controlled, phase 3 study (FRESCO-2) at 124 hospitals and cancer centres across 14 countries. We included patients aged 18 years or older (≥20 years in Japan) with histologically or cytologically documented metastatic colorectal adenocarcinoma who had received all current standard approved cytotoxic and targeted therapies and progressed on or were intolerant to trifluridine-tipiracil or regorafenib, or both. Eligible patients were randomly assigned (2:1) to receive fruquintinib (5 mg capsule) or matched placebo orally once daily on days 1-21 in 28-day cycles, plus best supportive care. Stratification factors were previous trifluridine-tipiracil or regorafenib, or both, RAS mutation status, and duration of metastatic disease. Patients, investigators, study site personnel, and sponsors, except for selected sponsor pharmacovigilance personnel, were masked to study group assignments. The primary endpoint was overall survival, defined as the time from randomisation to death from any cause. A non-binding futility analysis was done when approximately one-third of the expected overall survival events had occurred. Final analysis occurred after 480 overall survival events. This study is registered with ClinicalTrials.gov, NCT04322539, and EudraCT, 2020-000158-88, and is ongoing but not recruiting.Findings Between Aug 12, 2020, and Dec 2, 2021, 934 patients were assessed for eligibility and 691 were enrolled and randomly assigned to receive fruquintinib (n=461) or placebo (n=230). Patients had received a median of 4 lines (IQR 3-6) of previous systemic therapy for metastatic disease, and 502 (73%) of 691 patients had received more than 3 lines. Median overall survival was 7·4 months (95% CI 6·7-8·2) in the fruquintinib group versus 4·8 months (4·0-5·8) in the placebo group (hazard ratio 0·66, 95% CI 0·55-0·80; p<0·0001). Grade 3 or worse adverse events occurred in 286 (63%) of 456 patients who received fruquintinib and 116 (50%) of 230 who received placebo; the most common grade 3 or worse adverse events in the fruquintinib group included hypertension (n=62 [14%]), asthenia (n=35 [8%]), and hand-foot syndrome (n=29 [6%]). There was one treatment-related death in each group (intestinal perforation in the fruquintinib group and cardiac arrest in the placebo group).Interpretation Fruquintinib treatment resulted in a significant and clinically meaningful benefit in overall survival compared with placebo in patients with refractory metastatic colorectal cancer. These data support the use of fruquintinib as a global treatment option for patients with refractory metastatic colorectal cancer. Ongoing analysis of the quality of life data will further establish the clinical benefit of fruquintinib in this patient population.Funding HUTCHMED.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)00772-9

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

See all 418

Metadata

Authors
Dasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., Sartore-Bianchi, A., Satoh, T., Randrian, V., Tomasek, J., Chong, G., Paulson, A. S., Masuishi, T., Jones, J., Csőszi, T., Cremolini, C., Ghiringhelli, F., Shergill, A., Hochster, H. S., Krauss, J., Bassam, A., Ducreux, M., Elme, A., Faugeras, L., Kasper, S., Van Cutsem, E., Arnold, D., Nanda, S., Yang, Z., Schelman, W. R., Kania, M., Tabernero, J., & Eng, C.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Istituto Oncologico Veneto (IT)
  • National Cancer Center Hospital East (JP)
  • Ospedale Policlinico San Martino (IT)
  • Bács-Kiskun Megyei Kórház (HU)
  • Osaka University Hospital (JP)
  • Université de Poitiers (FR)
  • Austin Hospital (AU)
  • Aichi Cancer Center (JP)
  • Mayo Clinic in Florida (US)
  • University of Pisa (IT)
  • University of Chicago (US)
  • University of Michigan (US)
  • Békés Megyei Központi Kórház (HU)
  • Inserm (FR)
  • North Estonia Medical Centre (EE)
  • CHU Dinant Godinne UCL Namur (BE)
  • Essen University Hospital (DE)
  • Asklepios Klinik Altona (DE)
  • HUTCHMED (China) Limited (China) (HK)
  • Vall d'Hebron Institute of Oncology (ES)
  • Vanderbilt University (US)
Corresponding author
Dasari, Arvind
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-07
Volume
402
Issue
10395
Pages
41-53
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4380887702
Cited by
368
References
17
Citations by year
2026: 115 · 2025: 133 · 2024: 106 · 2023: 14
FWCI
46.11
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • Digital Access to Libraries (submittedVersion, other-oa)
Funders
Japan Society for the Promotion of Science (22K19559, 23K24405)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
fruquintinib, metastatic colorectal cancer, VEGFR inhibitors, refractory colorectal cancer, overall survival, trifluridine/tipiracil, regorafenib, RAS mutations, best supportive care, oral targeted therapy, safety and tolerability, RAS mutation status
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Benzofurans, Colonic Neoplasms, Double-Blind Method, Humans, Phenylurea Compounds, Pyridines, Quality of Life, Quinazolines, Rectal Neoplasms, Trifluridine, Colorectal Neoplasms, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00772-9
The paper
Dasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., Sartore-Bianchi, A., Satoh, T., Randrian, V., Tomasek, J., Chong, G., Paulson, A. S., Masuishi, T., Jones, J., Csőszi, T., . . . Eng, C. (2023). Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet. https://doi.org/10.1016/s0140-6736(23)00772-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.